These results indicate that Slit2N/Robo4 modulates several key cellularfunctions, which contribute to lymphangiogenesis, and identify thisligand-receptor pair as a potential therapeutic target to inhibit lymphaticmetastasis of VEGF-C-overexpressing cancers and manage lymphaticdysfunctions characterized by VEGF-C/VEGFR-3 activation. Here, FLT4 is linked to cancer.